Abstract
The aim of this work is to develop and validate a microbiological assay for ceftriaxone with a view to the employment of this method to assess photo-stability in commercial products. The experimental conditions included: (1) ceftriaxone standard solution in concentrations of 2.6 μg/mL, 3.2 μg/mL, 4.0 μg/mL, 5.0 μg/mL and 6.3 μg/mL, using phosphate buffer pH 6.0 as diluent, (2) Petri dishes prepared by adding 21-mL of antibiotic medium as base layer and 4-mL of the same medium, inoculated with Bacillus subtilis (ATCC 6633) in a proportion of 0.5% and (3) incubation at 37ºC for 18 hours. The method showed specificity, good linearity in the range from 2.6 to 6.3 μg/mL, as well as good precision (RSD repeatability of 1.7% and RSD intermediate precision of 2.2%) and accuracy (recovery of 101.1%). Commercial samples of ceftriaxone were exposed to light in their primary and secondary packing, being afterwards directly exposed to light. The potencies of commercial samples were then determined by the developed and validated microbiological assay. The results indicate that primary and secondary packing provide satisfactory protection of ceftriaxone from light.
Keywords: Agar diffusion, Antibiotic assay, Ceftriaxone, Cephalosporin, Dosage form, Method development, Method validation, Microbial assay, Photo-stability, Stability study
Current Pharmaceutical Analysis
Title:Development and Validation of Microbiological Assay for Ceftriaxone and its Application in Photo-stability Study
Volume: 9 Issue: 1
Author(s): Felipe Rebello Lourenco, Marcus Augusto Lyrio Traple, Rogerio Takao Okamoto and Terezinha de Jesus Andreoli Pinto
Affiliation:
Keywords: Agar diffusion, Antibiotic assay, Ceftriaxone, Cephalosporin, Dosage form, Method development, Method validation, Microbial assay, Photo-stability, Stability study
Abstract: The aim of this work is to develop and validate a microbiological assay for ceftriaxone with a view to the employment of this method to assess photo-stability in commercial products. The experimental conditions included: (1) ceftriaxone standard solution in concentrations of 2.6 μg/mL, 3.2 μg/mL, 4.0 μg/mL, 5.0 μg/mL and 6.3 μg/mL, using phosphate buffer pH 6.0 as diluent, (2) Petri dishes prepared by adding 21-mL of antibiotic medium as base layer and 4-mL of the same medium, inoculated with Bacillus subtilis (ATCC 6633) in a proportion of 0.5% and (3) incubation at 37ºC for 18 hours. The method showed specificity, good linearity in the range from 2.6 to 6.3 μg/mL, as well as good precision (RSD repeatability of 1.7% and RSD intermediate precision of 2.2%) and accuracy (recovery of 101.1%). Commercial samples of ceftriaxone were exposed to light in their primary and secondary packing, being afterwards directly exposed to light. The potencies of commercial samples were then determined by the developed and validated microbiological assay. The results indicate that primary and secondary packing provide satisfactory protection of ceftriaxone from light.
Export Options
About this article
Cite this article as:
Rebello Lourenco Felipe, Augusto Lyrio Traple Marcus, Takao Okamoto Rogerio and de Jesus Andreoli Pinto Terezinha, Development and Validation of Microbiological Assay for Ceftriaxone and its Application in Photo-stability Study, Current Pharmaceutical Analysis 2013; 9 (1) . https://dx.doi.org/10.2174/1573412911309010011
DOI https://dx.doi.org/10.2174/1573412911309010011 |
Print ISSN 1573-4129 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-676X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Evidence on the Evaluation and Management of Fever Without a Source in Infants Aged 0-90 Days: A Review
Reviews on Recent Clinical Trials Astrocytes: Adhesion Molecules and Immunomodulation
Current Drug Targets Radiation Therapy in the Early 21st Century: Technological Advances
Current Cancer Therapy Reviews Molecular Biology of Nucleoside Transporters and their Distributions and Functions in the Brain
Current Topics in Medicinal Chemistry Headache: One of the Most Common and Troublesome Adverse Reactions to Drugs
Current Drug Safety Mechanisms of Drug Hypersensitivity Reactions and the Skin
Recent Patents on Inflammation & Allergy Drug Discovery Properties and Potency of Small Molecule Agents for Treatment of Mycobacterium Tuberculosis Infections of the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Functions of Fukutin, a Gene Responsible for Fukuyama Type Congenital Muscular Dystrophy, in Neuromuscular System and Other Somatic Organs
Central Nervous System Agents in Medicinal Chemistry Bacteriophages as Therapeutic and Prophylactic Means: Summary of the Soviet and Post Soviet Experiences
Current Drug Delivery Cefepime and its Role in Pediatric Infections
Recent Patents on Anti-Infective Drug Discovery Exploring Optic Nerve Axon Regeneration
Current Neuropharmacology Giant Cell Arteritis – A Series of Cases and Review of Literature
Current Rheumatology Reviews Past, Recent Progresses and Future Perspectives of Nanotechnology Applied to Antifungal Agents
Current Drug Metabolism Neuroimmune Crosstalk in CNS Disorders: The Histamine Connection
Current Pharmaceutical Design Highlights in the Development of New Antiviral Agents
Mini-Reviews in Medicinal Chemistry Brain Permeable Nanoparticles
Recent Patents on CNS Drug Discovery (Discontinued) Current Status Of Short Synthetic Peptides As Vaccines
Medicinal Chemistry Understanding the Use of Immunosuppressive Agents in the Clinical Management of IBD
Current Drug Targets Current Understanding of Polymyxin B Applications in Bacteraemia/ Sepsis Therapy Prevention: Clinical, Pharmaceutical, Structural and Mechanistic Aspects
Anti-Infective Agents in Medicinal Chemistry Management of Spasticity in Progressive Multiple Sclerosis: Efficacy of Repeated Intrathecal Triamcinolone Acetonide Administration
Current Pharmaceutical Design